Impact on follow-up strategies in patients with primary sclerosing cholangitis.
Bergquist A, Weismüller TJ, Levy C, Rupp C, Joshi D, Nayagam JS, Montano-Loza AJ, Lytvyak E, Wunsch E, Milkiewicz P, Zenouzi R, Schramm C, Cazzagon N, Floreani A, Liby IF, Wiestler M, Wedemeyer H, Zhou T, Strassburg CP, Rigopoulou E, Dalekos G, Narasimman M, Verhelst X, Degroote H, Vesterhus M, Kremer AE, Bündgens B, Rorsman F, Nilsson E, Jørgensen KK, von Seth E, Cornillet Jeannin M, Nyhlin N, Martin H, Kechagias S, Wiencke K, Werner M, Beretta-Piccoli BT, Marzioni M, Isoniemi H, Arola J, Wefer A, Söderling J, Färkkilä M, Lenzen H; International PSC Study Group.
Bergquist A, et al.
Liver Int. 2023 Jan;43(1):127-138. doi: 10.1111/liv.15286. Epub 2022 May 16.
Liver Int. 2023.
PMID: 35535655
Free PMC article.
Patients were followed from the start of scheduled imaging or in case of clinical follow-up from 1 January 2000, until death or last clinical follow-up alive. The primary endpoint was all-cause mortality. ...Multiple factors may contribute to this result including early tu …
Patients were followed from the start of scheduled imaging or in case of clinical follow-up from 1 January 2000, until death or last …